Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and
infection. A majority of people with cystic fibrosis have large quantities of bacteria
residing in their lungs. One of the most common and harmful bacteria is called Pseudomonas
aeruginosa.
Patients with cystic fibrosis require frequent therapy with intravenous (I.V.) antibiotics to
treat lung infections thought to be caused by Pseudomonas aeruginosa. One of the antibiotics
frequently used to treat this bacteria is piperacillin-tazobactam. Piperacillin-tazobactam is
thought to be the most effective when there is a constant level of drug in the body. The
standard way to administer piperacillin-tazobactam is to give several grams 4 times each day
as a 30 minute infusion. An alternative way to give piperacillin-tazobactam is by a
continuous infusion; a continuous infusion will make it more likely that drug will remain at
a constant level in the body. The objective of this study is to determine if administering
piperacillin-tazobactam as a continuous infusion is more effective at treating people having
a pulmonary exacerbation of cystic fibrosis than a standard 30 minute infusion, 4 times a
day.
Phase:
Phase 4
Details
Lead Sponsor:
West Virginia University
Treatments:
Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam